Fertility and Sterility
Volume 90, Issue 1 , Pages 17-22, July 2008

Use of the levonorgestrel-releasing intrauterine system in breast cancer patients

  • Xuan Bich Trinh, M.D.

      Affiliations

    • Department of Obstetrics and Gynaecology, General Hospital St. Augustinus, Wilrijk, Belgium
    • Department of Gynaecologic Oncology, University Hospital Antwerp, Edegem, Belgium
    • Corresponding Author InformationReprint requests: Xuan Bich Trinh, M.D., Department of Obstetrics and Gynaecology, St. Augustinus General Hospital, Oosterveldlaan 24, 2610 Wilrijk, Belgium (FAX: 32-3-443-30-36).
    • ,
  • Wiebren A.A. Tjalma, M.D., Ph.D.

      Affiliations

    • Department of Gynaecologic Oncology, University Hospital Antwerp, Edegem, Belgium
    • ,
  • Amin P. Makar, M.D., Ph.D.

      Affiliations

    • Department of Gynaecologic Oncology, The Middelheim Hospital, Antwerp, Belgium
    • Department of Gynaecologic Oncology, University Hospital Ghent, Ghent, Belgium
    • ,
  • Guy Buytaert, M.D.

      Affiliations

    • Department of Obstetrics and Gynaecology, Klina Hospital, Brasschaat, Belgium
    • ,
  • Joost Weyler, M.D., Ph.D.

      Affiliations

    • Department of Epidemiology and Social Medicine, University of Antwerp, Wilrijk, Belgium
    • ,
  • Peter A. van Dam, M.D., Ph.D.

      Affiliations

    • Department of Obstetrics and Gynaecology, General Hospital St. Augustinus, Wilrijk, Belgium

Received 30 December 2006; received in revised form 29 May 2007; accepted 29 May 2007. published online 14 August 2007.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 P.A.v.D. participated in a phase III trial for Schering and has been an invited speaker for Schering, Organon, Astra Zeneca, and Novartis.

PII: S0015-0282(07)01200-9

doi:10.1016/j.fertnstert.2007.05.033

Fertility and Sterility
Volume 90, Issue 1 , Pages 17-22, July 2008

Article Tools

* Image Usage & Resolution